Pharmafile Logo
Pharmafocus logo
Advanced Search

Mallinckrodt

Showing 5 posts of 5 posts found.

Mallinckrodt illegally inflated price of drug from $50 to $32,000, DoJ lawsuit says

June 7, 2019
Business Services Achthar, DoJ, Mallinckrodt, Medicare, co-pay, pharma

The Department of Justice (DoJ) has filed new charges against Mallinckrodt alleging the Irish-listed firm illegally hiked the price of …

News

FDA rejects Mallinckrodt’s abuse-deterrent version of opioid painkiller Roxicodone

December 12, 2018
Research and Development, Sales and Marketing FDA, Mallinckrodt, Roxicodone, opioid crisis, opioids, pharma

Mallinckrodt has hit a snag in its quest to bring an abuse-deterrent version of Roxicodone (oxycodone hydrochloride) to market in …

News
baby-784607_960_720

Mallinckrodt gets two thumbs down from FDA for jaundice drug

May 4, 2018
Medical Communications, Sales and Marketing InfaCare, Mallinckrodt, biotech, drugs, pharma, pharmaceutical

Mallinckrodt paid $80 million, with a further $345 million dependent on milestones, to acquire InfaCare in the hope that the …

News
mallinckrodt

Mallinckrodt bolsters business with $1.2bn buyout

January 3, 2018
Research and Development, Sales and Marketing Mallinckrodt, drugs, pharma, pharmaceutical, sucampo

Mallinckrodt has endured a tough 2017, with its share price falling by half over the course of the year. This …

News
mallinckrodt-project

Company in 85,000% infant epilepsy drug price increase receives $100 million fine

January 23, 2017
Sales and Marketing Mallinckrodt, Martin Skhreli

Mallinckrodt Pharmaceuticals has hit the headlines for particularly dispiriting reasons – with further evidence of practise by some companies that …

News

Latest content

Eisai and Biogen’s Leqembi launched for Alzheimer’s treatment in China

June 28, 2024

AbbVie’s Tepkinly gains positive CHMP opinion for follicular lymphoma treatment

June 28, 2024

IDEAYA Biosciences announces first-patient-in for phase 1 clinical trial evaluating IDE397 and Trodelvy combination in MTAP-deletion bladder cancer

June 27, 2024

Immunotherapy created at Roswell Park Comprehensive Cancer Center given expanded ODD by FDA

June 27, 2024

Abcuro completes enrolment for phase 2/3 IBM treatment trial

June 26, 2024